Rein Therapeutics Inc. (RNTX)
RNTX Stock Price Chart
Explore Rein Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze RNTX price movements and trends.
RNTX Company Profile
Discover essential business fundamentals and corporate details for Rein Therapeutics Inc. (RNTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
29 Jun 2017
Employees
11.00
Website
http://www.reintx.comCEO
James Brian Windsor
Description
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
RNTX Financial Timeline
Browse a chronological timeline of Rein Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.27.
Earnings released on 15 May 2026
EPS came in at -$0.19 surpassing the estimated -$0.49 by +61.22%.
Earnings released on 26 Mar 2026
EPS came in at -$1.09 matching the estimated -$1.09.
Earnings released on 14 Nov 2025
EPS came in at -$0.21 surpassing the estimated -$0.24 by +12.50%.
Earnings released on 14 Aug 2025
EPS came in at -$0.28 falling short of the estimated -$0.22 by -27.27%.
Earnings released on 7 Apr 2025
EPS came in at -$0.26 falling short of the estimated -$0.14 by -85.71%.
Earnings released on 31 Dec 2024
EPS came in at -$1.89 falling short of the estimated -$0.46 by -310.68%.
Earnings released on 14 Nov 2024
EPS came in at -$0.27 falling short of the estimated -$0.25 by -8.00%.
Earnings released on 14 Aug 2024
EPS came in at -$0.45 falling short of the estimated -$0.25 by -80.00%.
Earnings released on 31 Mar 2024
EPS came in at -$0.86 falling short of the estimated -$0.14 by -512.00%.
Earnings released on 31 Dec 2023
EPS came in at -$1.54 falling short of the estimated -$0.16 by -840.03%.
Earnings released on 30 Sept 2023
EPS came in at -$0.40 falling short of the estimated -$0.20 by -101.16%.
Earnings released on 30 Jun 2023
EPS came in at -$0.39 surpassing the estimated -$0.40 by +1.62%.
Earnings released on 8 May 2023
Earnings released on 20 Mar 2023
Stock split effective on 11 Nov 2022
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
RNTX Stock Performance
Access detailed RNTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
